(Reuters) - BioDelivery Sciences International Inc said its pain drug failed to meet the main goal of a late-stage study, sending the drugmaker's shares down nearly 30 percent premarket.
The Clonidine topical gel was not effective against a placebo in treating painful diabetic neuropathy, BioDelivery said in a statement on Monday.
Also read: Bayer says asbestos-related tumor treatment misses key goal
Read more